Join our daily newsletter At The Bell to receive exclusive market insights
- Hydrix (HYD) signs a $1.48 million deal with Cyban to develop the Cyban next-generation brain oxygen monitor
- HYD will carry out detailed design, construction and testing of engineering prototypes, as well as final verification
- Cyban says its monitor can help enable early detection and faster treatment of brain hypoxia, which is a lack of oxygen to the brain
- Hydrix holds a 5.85 per cent stake in Cyban, which is targeting the commercial market launch of its brain monitor in 2024
- Shares in HYD are up 6.98 per cent to 4.6 cents at 11:53 am AEDT
Hydrix (HYD) has signed a $1.48 million deal with Cyban to help aid the development of the Cyban next-generation brain oxygen monitor.
HYD will offer its innovative expertise, carrying out detailed design, construction and testing of engineering prototypes, as well as final verification testing.
Hydrix General Manager Michael Trieu said the collaboration was an exciting opportunity for both parties.
“Our teams are working very collaboratively to accelerate the completion of the first generation of the product, which can potentially establish a new gold standard of care in brain trauma injury management,” Mr Trieu said.
The company aims to complete its testing efforts over the next sixth months.
Cyban’s world-first brain oxygen monitor continues to show positive signs towards how brain injuries are detected, treated and managed.
It said the monitor would help enable early detection and faster treatment of brain hypoxia, which refers to a lack of oxygen to the brain.
Hydrix holds a 5.85 per cent stake in Cyban, which is targeting the commercial market launch of its brain monitor in 2024.
Shares in HYD were up 6.98 per cent to 4.6 cents at 11:53 am AEDT.
